For research use only. This article describes a forthcoming FDA advisory-committee meeting and the section 503A regulatory framework that meeting addresses. Nothing here is legal advice; nothing here recommends any particular position on whether the substances under review should or should not appear on the 503A Bulks List. Optides supplies research-grade peptides for in-vitro laboratory work only — not for human or animal consumption — and the regulatory matters discussed below govern a separate human-use compounding channel. For full context, see our research-use disclaimer.
FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23 and 24, 2026, to discuss whether seven research peptides should be added to the section 503A Bulks List. The agenda: BPC-157, KPV, TB-500, and MOTS-c on July 23; Emideltide, Semax, and Epitalon on July 24. What follows explains what the 503A Bulks List actually is, what's on the agenda in plain terms, the three nomination categories used during evaluation, the PCAC's advisory role versus FDA's final-decision authority, and what the outcomes mean — and don't mean — for research-grade peptide supply.
What's happening on July 23-24, 2026
The PCAC is the federal advisory committee that recommends to FDA which bulk drug substances should appear on the lists permitted for pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The committee's role is advisory; the agency decides. PCAC meets several times a year. What's distinctive about the July 2026 meeting is the size of the slate — the largest single batch of research-peptide nominations to come up for review in one session.
July 23 agenda
According to FDA's published meeting notice, the July 23 session will discuss BPC-157, KPV, TB-500, and MOTS-c. Each substance appears on the agenda in both free-base and acetate forms — that is, the committee will evaluate the chemistry of the parent compound and of the salt typically supplied for compounding. Nominators of each substance are invited to make short presentations supporting the nomination.
July 24 agenda
The July 24 session will discuss Emideltide, Semax, and Epitalon under the same format. The two-day structure groups peptides with broadly similar regulatory questions together; the day-to-day breakdown is a logistical choice and does not signal anything about FDA's evaluation of any individual substance.
Why this meeting matters
The 503A Bulks List is the gating document for whether a given bulk drug substance is permitted in 503A pharmacy compounding. Inclusion opens a regulated compounding channel for a substance; exclusion closes it. The July 2026 outcomes will affect every one of the seven peptides on the agenda — and the same outcomes will be cited in industry coverage of the broader research-peptide regulatory landscape for years afterward.
What section 503A and the Bulks List actually are
The framework is widely misunderstood, so the plain-language version is worth covering carefully. Section 503A of the FD&C Act exempts certain compounded drug preparations from the new-drug-approval, current-good-manufacturing-practice, and labeling requirements that otherwise apply under federal law. The exemption is not unconditional — it applies only when the bulk drug substance used in the preparation appears on one of three lists: the United States Pharmacopeia or National Formulary, an approved drug application list, or the FDA-published 503A Bulks List. FDA's guidance for industry walks through the structure in detail.
The Bulks List versus the safety-risk list
Two FDA-published lists are commonly conflated. The 503A Bulks List is a positive list — substances on it are permitted in 503A compounding. The "Certain Bulk Drug Substances That May Present Significant Safety Risks" list is a negative list — substances on it cannot be used in compounded preparations regardless of any other consideration. A substance can be reviewed and rejected from the Bulks List without ending up on the safety-risk list; the two outcomes are distinct.
How a substance gets onto the Bulks List
The path runs through a public-nomination process. Anyone — a compounding pharmacy, a trade group, an academic researcher — can nominate a substance. FDA then evaluates the nomination, the historical-use record, the available safety and efficacy data, and any public comments received. The PCAC reviews FDA's evaluation alongside the original nomination and provides a recommendation. FDA makes the final placement decision and publishes it in the Federal Register and on FDA's website.
The peptides under review in July 2026
Each of the seven peptides on the July 2026 agenda is a chemically well-defined research-grade compound with an established place in the in-vitro and animal-model literature. The list below summarizes each compound at the level of "what is it"; deeper structural and pharmacology coverage lives in the linked references.
BPC-157
BPC-157 (Body Protection Compound-157) is a 15-residue synthetic peptide derived from a fragment of a protein found in human gastric juice. It is on the July 23 agenda in both free-base and acetate forms. For the structural details and the in-vitro literature on BPC-157, see our BPC-157 structural reference.
KPV
KPV is a tripeptide with the sequence Lys-Pro-Val, derived from the C-terminal segment of α-melanocyte-stimulating hormone (α-MSH). It has been studied in cell-culture models for its anti-inflammatory signaling effects. On the July 23 agenda.
TB-500
TB-500 is the synthetic name for a 7-residue active fragment of thymosin β4, with the core sequence Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ). The peptide has been studied in the in-vitro literature for actin-binding and migration-related signaling. On the July 23 agenda.
MOTS-c
MOTS-c is a 16-residue mitochondrial-derived peptide encoded by the 12S rRNA gene of human mitochondrial DNA. It has been characterized in cell-culture models for its effects on metabolic signaling. On the July 23 agenda.
Emideltide
Emideltide is a synthetic peptide on the July 24 agenda. The PCAC briefing document released approximately two weeks before each meeting will summarize FDA's evaluation in detail.
Semax
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, an analog of the ACTH(4-7) fragment with a Pro-Gly-Pro extension. It has been studied in animal-model literature for neurochemical effects. On the July 24 agenda.
Epitalon
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It has been studied in cell-culture models for effects related to telomerase activity and cellular replicative capacity. On the July 24 agenda.
A note on framing
This article describes what is on the agenda — not whether each substance "should" be added to the 503A Bulks List. That analysis is exactly what the PCAC review process is for, and we don't anticipate the outcome here. The July 2026 briefing documents and meeting transcripts will be the primary sources for anyone who wants to follow each substance's evaluation in detail.
Three nomination categories: what they mean
FDA's interim policy describes three categories that nominated substances move through during evaluation. Understanding which category a substance is currently in is the difference between "may be used pending decision" and "may not be used at all". FDA's interim policy document defines the categories formally.
Category 1 — under evaluation
A Category 1 substance is under active FDA evaluation and may be used in compounded preparations pending the agency's final decision, subject to certain conditions. This is a temporary status, not an approval. Operators relying on a Category 1 substance should monitor FDA's published outcomes and updated guidance for status changes.
Category 2 — significant safety risk
A Category 2 substance has been identified by FDA as presenting significant safety risks for use in compounded human drug products. Substances in this category may not be used in 503A compounding. The decision is FDA's; PCAC may have recommended one way or the other, but the placement decision is the agency's.
Category 3 — withdrawn or insufficient data
A Category 3 substance is one whose nomination was withdrawn by the nominator, or for which the data submitted in support of the nomination was insufficient for FDA to evaluate. A Category 3 substance is not eligible for 503A use unless it is re-nominated with adequate supporting data.
What happens after July 2026
Each of the seven agenda substances will receive a category placement based on FDA's review plus the PCAC recommendation, published as a final rule in the Federal Register. The categorization timeline runs months — sometimes more than a year — beyond the meeting itself; operators should not expect a final published outcome on July 25.
The PCAC's advisory role and FDA's final-decision authority
One of the most common points of confusion in summary coverage of these meetings is the assumption that a PCAC vote determines whether a substance ends up on the 503A Bulks List. It does not. FDA's overview of the PCAC's role is explicit: the committee's recommendations are advisory only.
What FDA reviews before deciding
The agency considers the original nomination, FDA's own evaluation documents, the PCAC's recommendation, and any public comments received during the comment period. The final placement decision is FDA's alone. A PCAC recommendation in favor of inclusion does not guarantee FDA will agree, and a recommendation against inclusion does not guarantee FDA will exclude.
Briefing documents and public comment
FDA releases briefing documents approximately two weeks before each PCAC meeting. The briefing materials summarize FDA's review of each nominated substance, the safety and efficacy data on file, and the agency's preliminary assessment. The meetings themselves include a public-comment period, and submitted comments become part of the official record FDA considers when finalizing placement.
What this means for research-grade peptide supply
The 503A framework and the research-grade peptide supply chain are sometimes discussed as if they were the same thing. They are not. FDA's overview page covers the 503A framework as it actually operates.
Different supply channels, different regulatory frameworks
503A pharmacy compounding governs human-use preparations dispensed by licensed pharmacists pursuant to a valid prescription. Research-grade peptide supply governs laboratory-only material, sold for in-vitro research, with no human-use intended or authorized. The chemistry of the molecule may be identical between the two channels, but the regulatory framework, intended use, quality-control posture, and downstream handling differ throughout.
What the July 2026 outcomes will and won't determine
Inclusion on the 503A Bulks List opens the 503A compounding channel for a substance. Exclusion (Category 2 or Category 3) closes that channel. Neither outcome directly determines whether a substance can continue to be sold as research-grade material; that question is governed by a separate set of FDA enforcement priorities, the Federal Trade Commission's advertising-claim rules, and state-level chemical-supplier regulations. For broader context on the research-use legal framework, see our research-use legal landscape article.
What operators in the research-peptide space should watch
Read the briefing documents when they are released — typically two weeks before each meeting. Track whether each agenda substance ends up in Category 1, 2, or 3. Note that FDA's own enforcement priorities can shift independent of the Bulks List placement; an exclusion outcome does not, on its own, prohibit research-grade sale of the underlying chemical.
Frequently Asked Questions
What is the FDA 503A Bulks List?
Section 503A of the Federal Food, Drug, and Cosmetic Act exempts certain compounded drug preparations from the new-drug-approval, manufacturing, and labeling requirements that otherwise apply — but only when the bulk drug substance used appears on one of three lists: the USP/NF, an approved drug application list, or the FDA-published 503A Bulks List. The 503A Bulks List is the positive list of substances FDA has cleared for use in 503A pharmacy compounding.
Which peptides will the FDA PCAC discuss in July 2026?
The July 23-24, 2026 PCAC meeting is scheduled to discuss BPC-157, KPV, TB-500, and MOTS-c on July 23, and Emideltide, Semax, and Epitalon on July 24. Each appears in both free-base and acetate forms on the agenda. Nominators will be invited to make a short presentation supporting each nomination.
What is the difference between Category 1, 2, and 3?
Category 1 means the substance is under active evaluation and may be used in compounded preparations pending FDA's final decision, subject to certain conditions. Category 2 means FDA has identified the substance as presenting significant safety risks; it may not be used in compounding. Category 3 means the nomination was withdrawn or the data submitted was insufficient to evaluate. "Under evaluation" is not equivalent to "approved for compounding" — operators should monitor PCAC outcomes and updated FDA guidance for status changes.
Does the PCAC's recommendation determine whether a peptide ends up on the Bulks List?
No. The PCAC's role is advisory only. FDA reviews each nomination, the agency's own review documents, the PCAC's recommendation, and any public comments before making the final placement decision. A PCAC recommendation in favor of inclusion does not guarantee FDA will agree, and a recommendation against inclusion does not guarantee FDA will exclude. The final-decision authority rests with the agency.
How does this affect research-grade peptide supply?
The 503A framework governs human-use compounded preparations dispensed by licensed pharmacists with a prescription. Research-grade peptides sold for in-vitro laboratory work are a separate supply channel — the chemistry may be identical, but the regulatory framework, intended use, and quality-control posture differ. Inclusion or exclusion of a substance on the 503A Bulks List doesn't directly determine whether it can continue to be sold as research-grade material; that's governed by a different set of FDA enforcement priorities.
Conclusion
FDA's July 23-24, 2026 PCAC meeting will discuss seven research peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon — for potential addition to the section 503A Bulks List. The 503A Bulks List, the safety-risk list, the three nomination categories, and the PCAC-versus-FDA decision authority are all distinct regulatory concepts that summary coverage often conflates. The meeting outcomes will affect 503A compounding eligibility for each substance; they don't directly determine research-grade availability, which is governed by a different framework. For research use only.
For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.
Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.